Leruste et al. showed efficacy of anti-PD-1 monotherapy in a relevant immune-competent mouse model of ATRT, further suggesting a role of immunotherapy in SMARCB1-deficient cancers such as RMC [57]. The gene discussed is SMARCB1; the disease is atypical teratoid rhabdoid tumor.